Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25661047 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11GRIN2DGRIN3BGRIN1 | |
| SCHEMBL25660483 | 0.86 | KDM4E (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3917900 | 0.86 | KDM4E (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL75670 | 0.81 | — | — | |
| SCHEMBL75669 | 0.81 | — | — | |
| SCHEMBL2380451 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL21058970 | 0.79 | ANPEP (0.46) | PTGS1SLC7A11GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL21058967 | 0.79 | ANPEP (0.46) | PTGS1SLC7A11GRIN2DGRIN3BGRIN1 | |
| SCHEMBL841679 | 0.77 | SLC1A3 (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL287541 | 0.77 | SLC1A3 (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-4421854-A | MUTANT OF ARTHROBACTER | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | claimed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002469-A2 | THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-6939854-B2 | Peptide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6846806-B2 | Peptide inhibitors of Hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| US-4421854-A | MUTANT OF ARTHROBACTER | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | PTGS1 118/4885SLC7A11 2028/4885GRIN2D 4707/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | PTGS1 189/4885SLC7A11 2427/4885GRIN2D 2737/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | PTGS1 4864/4885SLC7A11 26/4885GRIN2D 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.